From Financial Modeling Prep: 2025-02-28 07:00:12

Lantheus Holdings, Inc. (NASDAQ:LNTH) specializes in innovative diagnostic and therapeutic products in the healthcare sector, particularly medical imaging and nuclear medicine. It competes with companies like ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

Lantheus has a strong Return on Invested Capital (ROIC) of 18.77%, exceeding its Weighted Average Cost of Capital (WACC) of 6.45%. This efficiency translates to a ROIC to WACC ratio of 2.91, indicating effective capital utilization and profitability for investors.

Comparatively, ShockWave Medical has a ROIC of 9.50% and a WACC of 8.26%, resulting in a lower efficiency with a ROIC to WACC ratio of 1.15. Medpace Holdings leads the group with a ROIC of 38.11% and a WACC of 10.44%, achieving the highest ROIC to WACC ratio of 3.65.

LivaNova has a ROIC of 5.16% and a WACC of 8.40%, resulting in an inefficient ROIC to WACC ratio of 0.61. Apellis Pharmaceuticals faces challenges with a negative ROIC of -31.12% and a WACC of 9.21%, leading to a ratio of -3.38, indicating significant capital utilization issues.

Natera also struggles with a negative ROIC of -17.73% and a WACC of 11.69%, resulting in a ratio of -1.52, highlighting financial inefficiencies. Despite strong competition, Lantheus Holdings emerges as a capital efficiency standout, while Medpace Holdings leads with the highest ROIC to WACC ratio in the peer group.



Read more at Financial Modeling Prep:: Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates…